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ABSTRACT 
Objective: To estimate time from HIV infection to linkage-to-care and its determinants. 
Linkage-to-care is usually assessed using the date of HIV diagnosis as the starting point for 
exposure time. However, timing of diagnosis is likely endogenous to linkage, leading to bias 
in linkage estimation. 
Design: We used longitudinal serosurveys from a large population-based HIV cohort in 
KwaZulu-Natal (2004-2013) to estimate time of HIV infection. We linked this data to patient 
records from a public-sector HIV treatment and care program to determine time from 
infection to linkage (defined using the date of the first CD4 count). 
Methods: We used Cox proportional-hazards models to estimate time from infection to 
linkage and the effects of the following covariates on this time: gender, age, education, food 
security, socio-economic status, area of residence, distance to clinics, knowledge of HIV 
status, and whether other household members have initiated ART. 
Results: We estimated that it would take an average of 4.9 years for 50% of seroconverters to 
be linked to care (95% confidence intervals (CI): 4.2-5.7). Among all cohort members that 
were linked to care, the median CD4 count at linkage was 350 cells/μL (95%CI: 330-380). 
Men and participants <30 years were found to have the slowest rates of linkage-to-care. Time 
to linkage became shorter over calendar time. 
Conclusions: Average time from HIV infection to linkage-to-care is long and needs to be 
reduced to ensure that HIV treatment-as-prevention policies are effective. Targeted 
interventions for men and young individuals have the largest potential to improve linkage 
rates. 
 
Keywords: HIV/AIDS; linkage to care; treatment cascade; care continuum; CD4 cell count; 
treatment-as-prevention; gender. 
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INTRODUCTION 
 Antiretroviral therapy (ART) improves patient outcomes, increases life expectancy, and 
reduces population-level transmission of HIV [1-3]. Timely linkage-to-care among the newly 
infected is important to maximize such individual and population-level benefits. The time from 
infection to linkage becomes especially relevant as HIV programs move from treatment to 
treatment-as-prevention. For treatment-as-prevention to achieve maximum success in reducing 
population-level incidence, linkage-to-care should ideally occur immediately following HIV 
infection for rapid ART initiation. In practice, however, several studies have found low linkage 
levels in sub-Saharan Africa [4-7]. A recent trial in rural KwaZulu-Natal (ANRS 12249) showed 
that low linkage-to-care was likely responsible for the failure to reduce population incidence 
through a community-based HIV treatment-as-prevention intervention [8, 9]. 
 While earlier evidence demonstrated substantial losses to follow-up after ART initiation 
in several settings [4, 10, 11], it has recently become clear that the losses in the early phases of 
the HIV care continuum are even more severe [6, 7, 12-17]. Most of this research relied on data 
from provider-initiated counselling and testing and, to a lesser extent, individuals using voluntary 
counselling and testing (community-based or home-based) [5]. Few studies used population-
based estimates of engagement in care [6-8]. Further, all the prior studies on linkage-to-care have 
in common that time to linkage was examined using the date of diagnosis, rather than the date of 
infection, as the starting point. Despite the urgency to improve early testing and treatment, 
substantial proportions of HIV-positive populations in sub-Saharan Africa still test late in the 
course of HIV disease [18]. Testing and treatment-seeking behaviors might be partly driven by 
perceived health status and examining the determinants of time to linkage-to-care from the date 
of infection, instead of date of HIV diagnosis (i.e., receipt of a first HIV positive test), can 
substantially advance our understanding of barriers to linkage – because the date of HIV 
diagnosis is likely endogenous to linkage rates. In other words, those who get diagnosed earlier 
are on average also more likely to link-to-care rapidly. Previous estimates of determinants of 
linkage-to-care are therefore potentially biased. 
In this study, we aim to estimate the time from HIV infection to linkage, as well as the 
determinants of this time. We use data from one of the largest population-based HIV incidence 
cohorts in Africa and link this data to patient records from the local public-sector HIV treatment 
and care program. Improving our understanding of the factors influencing time from HIV 
infection to linkage-to-care can substantially improve our ability to design and target 
interventions aimed at addressing barriers to early linkage and treatment initiation. Such 
interventions will be especially important for the success of HIV treatment-and-prevention 
policies and the attainment of the UNAIDS 90-90-90 targets [19]. 
METHODOLOGY 
Study population 
 Since 2000, the Africa Health Research Institute (AHRI) has operated longitudinal 
population health surveillance in rural KwaZulu-Natal (uMkanyakude district), South Africa 
[20]. Nested within the population health surveillance is one of Africa’s largest HIV incidence 
cohorts. Surveillance covers an area approximately 440 km2 in size, encompassing a population 
of 87,000 individuals (75,000 residents and 13,000 non-residents). It was designed to capture the 
complex and interwoven health, social, and demographic dynamics of a poor rural Southern 
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African population. In 2011, HIV prevalence in the adult population (15-50 years) was estimated 
at 29% and ART coverage of all HIV-positive adults was 31% [21]. 
 The AHRI population health surveillance collects information on all individuals who live 
in the surveillance area. The surveillance is conducted in two separate data collection 
approaches. First, every four months, a household survey is administered to a key informant to 
gather data on attributes and events regarding physical structure, households, and individual 
household members [20]. Second, every year trained field workers collect data through 
individual interviews, during which confidential HIV testing is offered to each adult. Eligibility 
criteria for the HIV serosurveys from 2003 to 2007 were all women aged 15-49 years and men 
aged 15-54 years old. After 2007, HIV testing was administered to all individuals aged 15 years 
and over. 
 ART became available in the area shortly after the national roll-out in 2004 [22]. At that 
time, HIV-positive individuals could only get access to treatment from the surveillance area’s 
hospital clinic. ART delivery has subsequently been scaled-up to 17 public-sector primary-care 
clinics in Hlabisa subdistrict; six of these clinics are located in the AHRI surveillance area [23]. 
The Hlabisa HIV Treatment and Care Program provides free HIV testing and counseling, 
condoms, and ART. In this study, linkage-to-care was operationalized as having a first CD4 
count, the required diagnostic criterion to assess ART eligibility during the time of this study, in 
the local HIV treatment and care program [22]. Further details on both the AHRI population 
health surveillance, the data collection in the HIV treatment and care program, and the data 
linkage between these two databases can be found elsewhere [1, 20, 22, 24]. 
Procedures and variables 
 Seroconverters are identified among repeated-testers. Repeated-testers are defined as the 
subset of individuals aged 15 years and older who had more than one HIV test performed during 
annual serosurveys, for which the first test was negative. Slightly modifying the approach used 
by Vandormael and colleagues [25], the date of HIV infection was proxied by estimating the date 
of seroconversion. Given the time lag between subsequent serosurveys, we could not directly 
ascertain the date of HIV seroconversion but it must have occurred in the interval between the 
last negative HIV test and the first positive HIV test in the population-based HIV incidence 
cohort. For our main analysis, we randomly assigned the date of infection between the last HIV 
negative test and the first HIV positive test, or first CD4 count test, whichever occurred first. A 
total of ten datasets with random imputation of HIV infection dates were constructed in that way. 
Random imputation allows us to propagate the uncertainty associated with the unobserved HIV 
infection dates to our results. For presentation of baseline descriptive statistics, we used the 
midpoint date between the last negative HIV test and first positive HIV test (or between the last 
negative HIV test and the first CD4 count test) for simplicity (hereafter referred to as ‘midpoint 
imputation’). Summary of the descriptive statistics of the ten imputed datasets can be found in 
supplemental materials (Table S1). Infections occurring before August 2004 were excluded since 
ART had not been rolled-out prior to that date and the individuals were hence not eligible for the 
outcome (i.e., linkage-to-care). Seroconverters in the AHRI population health surveillance and 
HIV incidence cohort were linked to the HIV treatment and care program database, using the 
South African identification number (or if missing, full names, sex, and birth date). Linkage-to-
care is defined in this study as having a first CD4 count test performed following HIV infection, 
as per the Hlabisa Treatment and Care Program’s protocol.  
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 Time to linkage-to-care was explored using time-varying covariates. The dynamic nature 
of the AHRI population cohort is captured through exposure episodes. Specifically, an exposure 
episode starts on the first day of the year and usually ends on the last day of that calendar year. If 
an individual changes residency or migrates inside or outside of the surveillance area, a new 
exposure episode is created for that period. Exposure episodes are thus of variable lengths and 
seroconverters can only live in one residence at a time (but multiple household memberships are 
allowed). All individuals who migrated out of the surveillance area, even temporarily, were 
censored on their emigration day. If an individual’s infection date was estimated to have 
occurred while outside of the surveillance area, this person was excluded. Hence, the ten 
randomly imputed datasets may have slightly different sample sizes and person-time of follow-
up. If seroconverters were not found to be linked to HIV care, they were censored on their last 
day of follow-up, the date they died, or January 2014 – whichever occurred first. 
 The main outcome of this study is time from HIV infection to linkage-to-care. The only 
time-invariant variables considered are gender, knowledge of HIV status at baseline (i.e., first 
positive test), and the calendar year of infection. Time-varying variables are: age, area of 
residence, socio-economic status (asset-based index categorized into quartiles, among 
seroconverters, using the first axis of a principal component analysis of 21 household assets), 
education level, whether one’s household co-members are receiving ART, and the Euclidian 
distance to the closest health facility where ART is provided. Since some of the exposure 
episodes are retrospectively constructed (i.e., they are within two survey dates), we assigned 
them based on the closest survey date (but not more than one year after the beginning of the 
exposure episode). Household-level variables were attributed based on household residence and 
closest survey date. For missing education level values, if an individual was aged 19 years or 
above and had at least one observation with information on education level, we imputed that 
value using the previously reported education level. 
Statistical analyses 
 Time from HIV infection to linkage-to-care was first explored using Kaplan-Meier 
estimates of the survival curve. CD4 counts at linkage, stratified by time to linkage-to-care, were 
also examined. Cox proportional hazards models were then used to estimate the effect of the 
different variables on time to linkage-to-care. Covariates with missing observations were 
retained in the analysis using the missing indicator method [26]. We present results for univariate 
and multivariable models. Because the question about knowledge of HIV status was not part of 
the questionnaire in 2004 and 2005, the multivariable model only included observations from 
individuals who seroconverted from 2006 onwards. The method of Grambsch and Therneau [27], 
based on the scaled Schoenfeld residuals, was used to test that all variables met the proportional 
hazards assumption. Because some covariates failed that test, we stratified the survival analyses 
using the calendar year of HIV infection. All analyses were performed individually on the 10 
imputed datasets and results were combined with Rubin’s rule [28] using the R statistical 
software [29]. The ‘survival’ package [30] was used to fit the Cox proportional hazards models.  
Ethics 
 All respondents provided informed consent. The Biomedical Research Ethics Committee 
of the University of KwaZulu-Natal granted ethical approval for data collection. 
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RESULTS 
 Among individuals that were believed to have seroconverted between August 2004 and 
December 2013, 10 were found to have been linked to care before their last negative test and 
were therefore excluded from our analyses. Since they were potentially outside of the Hlabisa 
Treatment and Care Program’s catchment area, individuals not recorded to be in the surveillance 
area at their estimated time of HIV infection were also excluded. Hence, and depending on the 
randomly imputed seroconversion dates, between 1,713 and 1,779 recent seroconverters 
contributed between 4,582 and 4,818 person-years of follow-up to our inferences. Results from 
the midpoint imputation and the randomly imputed datasets differed principally with regards to 
the uncertainty around the different estimates but not regarding the effect size estimates (see 
supplemental material Tables S2-S4 and Figures S1S2). 
 Baseline characteristics of recent seroconverters are presented in Table 1. The great 
majority (77%) of recent seroconverters were women and over 70% had some or completed 
secondary education. Mean age at HIV infection was 27 years. Most recent seroconverters did 
not have members of their household who had initiated ART. 63% of seroconverters responded 
that they were aware of their HIV status at the time of their first positive test. The median time 
between last negative test and first positive HIV test was 2.0 years (interquartile range (IQR): 
1.1-3.2 years; with a maximum of 10 years). 
 Averaging over the imputed datasets, the median follow-up time was 2.2 years (IQR 1.1-
3.9) and only 14% of those who were followed-up for a minimum of 12 months had a CD4 count 
test performed within that time-period (this rises to 29% two years after HIV infection). At 
linkage, the median CD4 count was 350 cells/μL (95%CI: 330 to 380) (Table 2). Seroconverters 
that were linked to care in less than one year had a higher median CD4 cell count (370 cells/μL; 
95%CI: 320 to 410) than those that linked more than five years after infection (290 cells/μL; 
95%CI: 160 to 430). A total of 40 recent seroconverters died before being linked to care after a 
median follow-up time of 3.0 years (IQR: 1.9-4.7) after infection. The pooled Kaplan-Meier 
estimates of time from HIV infection to linkage-to-care are presented in Figure 1. From this, we 
estimate that it would have taken an average of 4.9 years (95%CI: 4.2 to 5.7) for 50% of 
seroconverters to be linked to care (Table 3). Time to linkage-to-care differed by gender: it took 
about 1.7 years (95%CI: 1.5-2.0) for 25% of women to link to care versus 3.4 years (95%CI: 2.4-
4.4) for men. Time to linkage-to-care also decreased with calendar time with 25% of 
seroconverters linking in 3.7 years (95%CI: 2.4-5.0) for those who acquired their infection in 
2004 to 1.4 years (95%CI: 0.6-2.2) for those who did so in 2010. 
 In univariate analyses, the main determinants of time to linkage-to-care were gender, age, 
education level, and knowledge of HIV status from previous testing (Table 4). As compared with 
females, males had roughly half the hazards of being linked to care (adjusted Hazard Ratio 
[aHR]=0.49; 95%CI 0.37-0.64). Seroconverters in the 40-49 years of age category had hazards 
54% higher (95%CI: 14-108%) of being linked to care as compared to seroconverters aged 15-29 
years old. Individuals with some or completed secondary education had lower hazards of being 
linked to care than those with a year or less of education (aHR=0.63; 95%CI: 0.39-1.00). 
Household co-memberships with individuals who had previously initiated ART increased the 
hazards of being linked to care by 23% (95%CI: -2 to 55%) but the confidence intervals of this 
estimate crossed the null. Finally, the hazards of being linked to care for individuals that are 
aware of their HIV status from previous testing were 35% (95%CI: 9 to 68%) higher than those 
who were unaware of their status or who refused to answer the survey question. 
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DISCUSSION 
 We estimated that it has taken an average of 4.9 years for 50% of seroconverters to be 
linked to care during 2004-2013. Comparisons with other empirical data is difficult because time 
to linkage-to-care has been defined in the past using HIV diagnosis as the starting point. To the 
best of our knowledge, this study is the first to measure time to linkage-to-care using a direct 
estimate of the HIV infection date as a starting point. Our empirical estimate of time from HIV 
infection to linkage is highly policy-relevant because it is a minimum bound on the length of 
time during which HIV-positive individuals can transmit HIV before the transmission risk is 
potentially eliminated through HIV treatment [31]. Our results indicate that substantial linkage 
improvements will be needed to maximize population-level benefits of both HIV treatment and 
HIV treatment-as-prevention. 
 With close to a quarter of patients dying within their first year on ART [31], not only is 
earlier initiation required, but also earlier diagnosis. We estimated that the median CD4 counts at 
linkage-to-care were of 370 cells/μL for individuals linking within one year of HIV infection and 
290 cells/μL for those linking five years or more after HIV infection. Several reasons could 
explain that the median CD4 count for individuals linking to care within one year was below 500 
cells/μL. First, the observed time lag between the last negative and first positive HIV test had a 
median of 2 years. Non-differential misclassification of the date of HIV infection could have 
biased our results toward the overall median CD4 count of individuals linking to care. Second, 
rates of decline in CD4 counts follow an unobserved distribution that we can estimate only 
among those individuals who linked to care. If linkage is a function of health status, which has 
been shown in other studies [15, 32], those with rapid disease progression and lower CD4 cell 
counts will link to care faster. The resulting median CD4 count since time from HIV infection is 
thus likely lower among our sample of individuals that linked to care than the median CD4 count 
since time from HIV infection among all HIV-positive people. 
 In this mostly poor and rural population, rates of linkage-to-care were twice as high for 
females as those of males, substantiating previous research [5, 6, 33]. The same was true for age, 
with seroconverters in the 40-49 years old range having the highest rates of linkage-to-care. 
Having other household members who previously initiated ART tended to reduce time to 
linkage-to-care. This finding provides some limited evidence that family and social exposure 
HIV treatment can facilitate linkage and ART uptake. 
 Diagnosing HIV is the first, and necessary step, on the HIV treatment cascade. We 
estimated that 63% of individuals were aware of their HIV status at their first positive HIV test 
during the annual serosurveys and this was a predictor of linkage-to-care. Yet, linkage-to-care 
was low and delayed in this cohort of seroconverters. This finding could be partly due to the 
eligibility criteria for ART from 2004 to 2010. During those years, only individuals with CD4 
count less than 200 cells/μL were eligible for ART initiation. Compounding this effect are the 
previously described low pre-ART retention rates [16] and high disengagement from care in this 
cohort [11]. These findings are corroborated by those from the first phase of the ANRS 12249 
treatment-as-prevention trial, conducted in the same area as this study, which showed that the 
delays in linkage-to-care could compromise the population-level effectiveness of treatment-as-
prevention [8, 9]. Preliminary results from the trial suggest that treatment-as-prevention did not 
substantially reduce HIV incidence because ART coverage in both arms of the trial were similar 
[8, 9]. That is, the intervention failed to link-to-care a substantial proportion of people in early 
HIV infection stages. Our estimates of time to linkage-to-care are nevertheless different than 
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those from this trial because the latter did not define time to linkage based on date of HIV 
infection but date of diagnosis (the trial was not powered to examined time from HIV infection 
to linkage-to-care).  
 Great challenges will need to be overcome to maximize the public health benefits of ART 
in settings such as the community in which this study took place. Several potential solutions have 
been proposed from point-of-care CD4 testing with home-based counseling and testing to health 
systems interventions and financial incentives [34, 35]. Yet, the quality of evidence for these 
proposed interventions is low and interventions often only target a single point in the HIV care 
continuum [34, 35][36]. More research is needed into multi-pronged approaches that would 
mitigate the individual, community, and structural barriers that delay linkage-to-care. 
 This study has some limitations. First, the exact date of HIV infection remains unknown 
and was estimated based on individuals who repeatedly participated in the annual population 
HIV surveillance surveys. Yet, random imputation of infection dates, resulting in non-differential 
measurement errors in time-to-event, generally introduces only small bias in the hazard ratio 
estimates [37, 38]. Further, we randomly imputed 10 datasets and the summary estimates we 
present included this uncertainty. Second, we cannot totally rule out that some individuals found 
to have seroconverted sought care outside of the Hlabisa Treatment and Care Program. 
Nevertheless, it is unlikely that the proportion of HIV positive individuals accessing ART 
outside of this public-sector program is higher than a few percent [24]. Low rates of health 
insurance makes private health care utilization, in particular for chronic diseases such as HIV, 
rare in this community [24]. 
 An important strength of this research is the use of population-based data, from one of 
Africa’s largest population-based HIV incidence cohorts, to estimate the time from HIV 
infection to linkage-to-care. Such estimates are likely more representative of the HIV-positive 
population than those derived from facility-based data. Other strengths include the definition of 
time to linkage-to-care based on date of HIV infection. To the best of our knowledge, this is the 
first study to use this definition, instead of the date of HIV diagnosis, which is likely to lead to 
substantial underestimates of time to linkage. Using a cohort of repeated testers to estimate 
infection date is more accurate than other approaches, such as back-calculation of seroconversion 
date based on CD4 cell counts at ART initiation or estimations based on tests for recent 
infections, which could introduce additional errors [39, 40]. Finally, we addressed a limitation of 
the extant literature on the determinants of linkage-to-care. Because HIV testing and diagnosis 
can, at least partly, be a function of health status and treatment-seeking behavior, using the date 
of diagnosis in survival analysis could lead to endogeneity biases. Our approach, based on the 
date of HIV infection rather than the diagnosis date, corrects for this potential bias. 
 In conclusion, large reductions in the time from HIV infection to linkage-to-care are 
required to realize the full potential of HIV treatment and HIV treatment-as-prevention in 
improving population health. Increasing HIV testing uptake and frequency, as well as 
interventions to improve linkage-to-care, in particular for men and young individuals, are likely 
good candidate interventions for shortening the time from infection to the first HIV clinic visit 
[41]. 
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Table 1: Baseline characteristics of recent seroconverters (using midpoint imputation; N=1,733) 
residing in the demographic surveillance area, South Africa (2004-2013). 
Variables Mean (SD) or Total (%) 
Gender  
   Female 1,333 (76.9%) 
   Male 400 (23.1%) 
Age (years) 26.8 (10.5) 
Education level  
   None or less than one year 103 (5.9%) 
   Some or completed primary 269 (15.5%) 
   Some or completed secondary 1,289 (74.4%) 
   Missing 72 (4.2%) 
Socio-economic status  
   Poorest  374 (21.6%) 
   Poor 435 (25.1%) 
   Rich 488 (28.2%) 
   Richest 435 (25.1%) 
   Missing 1 (0.1%) 
Food security  
   Never (or some months) missed meals 1,675 (96.7%) 
   Missing meals almost every month (financial reasons) 47 (2.7%) 
   Missing 11 (0.6%) 
Uptake of ART by household members  
   No household members on ART 1,463 (84.4%) 
   At least one household member on ART 270 (15.6%) 
Knowledge of HIV Status*  
   Aware 917 (63.3%) 
   Unaware / Refused  537 (36.7%) 
Area of residence  
   Urban 52 (3.1%) 
   Peri-urban 619 (35.7%) 
   Rural 1,061 (61.2%) 
Distance to closest health facility (km) 6.0 (9.1) 
Calendar year of HIV infection  
   2004 81 (4.7%) 
   2005 198 (11.4%) 
   2006 240 (13.8%) 
   2007 259 (14.9%) 
   2008 262 (15.1%) 
   2009 207 (11.9%) 
   2010 180 (10.4%) 
   2011 153 (8.8%) 
   2012 129 (7.4%) 
   2013 24 (1.4%) 
*The question about knowledge of HIV status from previous testing was not asked in 2004 
and 2005 (279 seroconverters were excluded). 
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Table 2: Median CD4 cell count (cells/μL) at linkage, stratified by linkage time since HIV 
infection, with 95% bootstrapped confidence intervals. 
Time from HIV infection to 
linkage-to-care 
Median CD4 cells/μL 
(95%CI*) 
Less than one year 370 (320, 410) 
Between one and two years 380 (340, 420) 
Between two and three years 360 (290, 430) 
Between three and four years 310 (230, 390) 
Between four and five years 320 (220, 410) 
More than five years 290 (160, 430) 
Overall 350 (330, 380) 
*95%CI=95% confidence intervals. These are based on 9,999 
bootstrap replicates. 
 
 
Table 3: Time from HIV infection (years) to linkage to care stratified by gender and calendar 
year of HIV infection. 
Characteristics 
Time from HIV 
infection for 25% of 
seroconverters to link to 
care (95%CI*) 
Time from HIV 
infection for 50% of 
seroconverters to link to 
care (95%CI*) 
Gender   
   Females 1.7 (1.5-2.0) 4.2 (3.7-4.6) 
   Males 3.4 (2.4-4.4) NA† 
Calendar year of HIV infection   
   2004 3.7 (2.4-5.0) 6.1 (3.7-8.5) 
   2005 3.1 (2.4-3.8) 5.6 (4.2-7.1) 
   2006 2.3 (1.7-2.9) 4.6 (3.3-6.0) 
   2007 1.6 (1.0-2.3) 4.0 (2.7-5.4) 
   2008 1.5 (1.0-2.0) NA† 
   2009 1.6 (1.0-2.2) NA† 
   2010 1.4 (0.6-2.2) NA† 
Overall 2.0 (1.8-2.2) 4.9 (4.2-5.7) 
 
*95%CI=95% confidence intervals. These are based on 9,999 bootstrap replicates. 
†NA=not available (the follow-up time was not long enough to observe 50% of seroconverters 
linking to care). 
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Figure 1. Pooled Kaplan-Meier estimates of time from HIV infection to linkage-to-care in rural 
Kwa-Zulu Natal South Africa (2004-2013) for A) all seroconverters and B) stratified by gender. 
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Table 4: Univariate and multivariable effect size estimates from Cox proportional hazard models 
of determinants of time from HIV infection to linkage-to-care in rural Kwa-Zulu Natal, South 
Africa. (Pooled results from the 10 imputed datasets.) 
Variables Univariate Multivariable* HR (95% CI) aHR (95% CI) 
GENDER   
   Male 0.49 (0.39-0.61) 0.49 (0.37-0.64) 
AGE   
   15-29 years old 1.00 1.00 
   30-39 years old 1.22 (0.96-1.55) 1.16 (0.86-1.57) 
   40-49 years old 1.92 (1.53-2.40) 1.54 (1.14-2.08) 
   50+ years old 1.15 (0.80-1.64) 0.87 (0.53-1.44) 
EDUCATION LEVEL   
   None or less than one year 1.00 1.00 
   Some or completed primary 0.87 (0.61-1.25) 0.75 (0.46-1.22) 
   Some or completed secondary 0.68 (0.50-0.93) 0.63 (0.39-1.00) 
FOOD SECURITY   
   Missing meals almost every month (financial reasons) 1.56 (0.88-2.79) 1.37 (0.67-2.80) 
SOCIO-ECONOMIC STATUS    
   Poorest 1.00 1.00 
   Poor 1.15 (0.90-1.46) 1.21 (0.91-1.61) 
   Rich 1.14 (0.90-1.44) 1.19 (0.75-1.90) 
   Richest 1.00 (0.78-1.29) 1.05 (0.62-1.79) 
OTHER HOUSEHOLD MEMBERS USING ART   
   At least one (versus ‘None’) 1.16 (0.96-1.41) 1.23 (0.98-1.55) 
KNOWLEDGE OF HIV STATUS*   
   Yes (versus ‘No / Refused’) 1.52 (1.24-1.87) 1.35 (1.09-1.68) 
AREA OF RESIDENCE   
   Urban 1.00 1.00 
   Peri-Urban 0.65 (0.42-1.02) 0.73 (0.43-1.24) 
   Rural 0.77 (0.49-1.21) 0.76 (0.45-1.30) 
DISTANCE TO HEALTH FACILITY   
   <2 km 1.00 1.00 
   2 to 4 km 1.04 (0.86-1.25) 1.00 (0.79-1.26) 
   >4 km 1.16 (0.93-1.45) 1.10 (0.84-1.44) 
CALENDAR YEAR OF HIV INFECTION Included as strata Included as strata 
 
HR (95%CI)=Hazard Ratio (95% Confidence Interval); aHR=adjusted Hazard Ratio. 
Results are presented after pooling the analyses of the 10 imputed datasets. All models were stratified using the 
calendar year of HIV infection to ensure that the proportional hazards assumption was met. The outcome variable was 
the time from HIV infection to linkage-to-care. We used the date of the first CD4 count test performed in the local HIV 
treatment and care program to identify the time from infection to linkage. 
*The question about knowledge of HIV status from previous testing was not asked in 2004 and 2005, hence, 
observations from these years were not included in the multivariable model. 
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INTRODUCTION 
 Antiretroviral therapy (ART) improves patient outcomes, increases life expectancy, and 
reduces population-level transmission of HIV [1-3]. Timely linkage-to-care among the newly 
infected is important to maximize such individual and population-level benefits. The time from 
infection to linkageTinkagehis becomes especially relevant as HIV programs move from 
treatment alone to a treatment-as-prevention approach. For treatment-as-prevention to achieve 
maximum success in reducing population-level incidence, linkage-to-care should ideally occur 
immediately following HIV infection for rapid ART initiationassessment of ART eligibility and 
enrolment in ART programs. In practice, however, severalmultiple studies have found 
inadequate low linkage levels and rates to and retention in care in sub-Saharan Africa [4-7]., and 
aA recent trial in rural KwaZulu-Natal (ANRS 12249) showed that low linkage-to-care was 
likely responsible for the failure to reduce population incidence through a community-based HIV 
treatment-as-prevention intervention [8, 9].  
 While earlier evidence demonstrated substantial losses to follow-up Loss-to-follow up 
after ART initiation in several settings has been well documented so far [4, 10, 11], it has 
recently become clear that the losses in the  and recent studies have shifted their attention to the 
early phases of the HIV care continuum are even more severe [6, 7, 12-17]. Most of this research 
relied on data from provider-initiated counselling and testing and, to a lesser extent, individuals 
using voluntary counselling and testing (community-based or home-based) [5]. Few studies used 
population-based estimates of engagement in care [6-8]. Further, all of the priorse studies on 
linkage-to-care have in common that time to linkage-to-care was examined using the date of 
diagnosis, rather than the date of infection, as the starting point. Despite the urgency to improve 
early testing and treatment, substantial proportions of HIV-positive populations in sub-Saharan 
Africa still test only late in the course of HIV disease [18]. Testing and treatment-seeking 
behaviors might be partly driven by perceived health status and examining the determinants of 
time to linkage-to-care from the date of infection, instead of date of HIV diagnosis (i.e., receipt 
of a first HIV positive test), can substantially advance our understanding of ould shed a different 
light on barriers to linkage – . Indeed,This is because the date of HIV diagnosis is likelycould be 
endogenous to linkage rates. In other words, those who get diagnosed earlier are on average 
could also be more likely to link-to-care rapidly. Previous estimates of determinants of linkage-
to-care are therefore potentially biased.  
In this studystudy, we aim to estimate the time from HIV infection to linkage, as well as 
the determinants of this time. We use  Using data from one of the largest population-based 
HIV incidence cohorts in Africa and linking thisese data to patient records from the locala 
public-sector HIV treatment and care program. , the aim of this study is to explore determinants 
of time from HIV infection to linkage-to-care in a rural area of South Africa. By using 
population-based HIV surveillance data we are not only able to identify the time of HIV 
infection, but we are also avoiding the selection effects that commonly plague participation in 
voluntary counselling and testing and other facility-based HIV testing approaches., we are able 
to make inferences on all HIV-positive individuals in the surveillance area, not just those with 
access to HIV testing. Improving our understanding of the factors influencing time from HIV 
infection to linkage-to-care can substantially improve our ability to design and target is critical to 
inform proper interventions aimed at addressing barriers to early linkage and prompt treatment 
initiation. Such interventions will be This is especially important for the success of HIV 
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treatment-and-prevention policies and the attainment of if the UNAIDS 90-90-90 targets is to be 
attained [19]. 
METHODOLOGY 
Study population 
 Since 2000, the Africa Centre for Health and Population StudiesHealth Research Institute 
(AHRIAfrica Centre) has operatedestablished a longitudinal population healthdemographic 
surveillance system in rural KwaZulu-Natal (uMkanyakude district), South Africa [20]. Nested 
within the population health surveillance is one of Africa’s largest HIV incidence cohorts. The 
population health surveillance and HIV incidence cohortSurveillance Africa Centre 
Demographic Information System (ACDIS) coverss an area approximately 440 km2 in size, 
encompassing a population of 87,000 individuals (75,000 residents and 13,000 non-residents). It 
was designed to capture the complex and interwoven health, social, and dynamic demographic 
dynamics of a poor rural Southern African population with very high HIV prevalence. realities of 
this population. The area is predominantly rural and poor with an urban township and informal 
peri-urban settlements. In 2011, HIV prevalence in the adult population (15-50 years) was 
estimated at 29% and ART coverage of all HIV-positive adults was 31% [21].  
 The ACDIS cohortAHRI population health surveillance collects information on all 
individuals members of households or family units locatedwho live in the surveillance area. The 
surveillance longitudinally follows three units of observation: individuals, households (which are 
socially defined), and residences (which are geographically defined). The surveillanceACDIS is 
conducted in two separate data collection approachescycles. First, Eevery foursix months, a 
household survey is administered to a key informant to gather data on attributes and events 
regarding physical structure, households, and individual household members [20]. Second, 
Conducted every year trained field workers collect through private interviews by trained field 
workers, the second type of survey collects data through individual interviews, during which 
confidential on individual members, including anonymous HIV testing is offered to each 
adult(i.e., test results are not disclosed to participants). Eligibility criteria for the HIV sero-
surveys from 2003 to 2007 were all women aged 15-49 years and men aged 15-54 years old. 
After 2007, HIV testing was administered to all individuals aged 15 years and over.  
 ART became available in the area shortly after the national roll-out in 2004 national roll-
out [22]. At that time, HIV-positive individuals could only get access to treatment from the 
surveillance area’s hospital clinic. ART delivery has subsequently been scaled-up to 17 public- 
sector primary- care clinics in Hlabisa subdistrict;  (six6 of these clinics are em being located in 
the AHRIACDIS surveillance area) [23]. The Hlabisa HIV Treatment and Care Program 
provides free HIV testing and counseling, condoms, and ART. This highly decentralized 
program, run by nurses and counselors, enrolls those testing positive in pre-ART counselling and 
health monitoring to determine ART eligibility [22, 23]. In this study, linkage-to-Enrollment in 
care wasis formally characterized byoperationalized as having a first CD4 count, the required 
diagnostic criterion to assess ART eligibility during the time of this study, in the local HIV 
treatment and care program [22]. During the time of this study, CD4 count was a required 
diagnostic criterion to assess ART eligibility. test performed. Patients’ treatment status is 
recorded and updated in the ART evaluation and monitoring system (ARTemis) database. 
Further details on both the AHRI population health surveillance, the data collection in the HIV 
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treatment and care program, and the data linkage between these two databases ACDIS and 
ARTemis can be found elsewhere [1, 20, 22, 24]. 
Procedures and variables 
 Seroconverters are identified among repeated-testers. Repeated-testers are defined as the 
subset of individuals aged 15 years and older who had more than one HIV test performed during 
annual sero-surveys, for which the first test was negative. Slightly modifying the approach used 
by Vandormael and colleagues [25], the date of HIV infection was proxied by estimating the date 
of seroconversion. Given the time lag between subsequent sero-surveys, we could not directly 
ascertain the date of HIV seroconversioninfection but it has tomust have occurred in the interval 
between the last negative HIV test and the first positive HIV test in the population-based HIV 
incidence cohort. For our main analysis, we randomly assigned the date of infection between the 
last HIV negative test and the first HIV positive test, or first CD4 count test, whichever occurred 
first. A total of ten10 datasets with random imputation of HIV infection dates were constructed 
in that way. Random imputation allows us to propagate to our results the uncertainty associated 
with the unobserved HIV infection dates to our results. For presentation of baseline descriptive 
statistics, we used the midpoint date between the last negative HIV test and first positive HIV 
test (or between the last negative HIV test and the first CD4 count test) for simplicity (hereafter 
referred to as ‘midpoint imputation’). Summary of the descriptive statistics of the ten10 imputed 
datasets can be found in supplemental materials (Table S1). Infections occurring before August 
2004 were excluded since ART had not been rolled-out prior to that date and the individuals 
were hence not eligible for the outcome (i.e., linkage-to-care). Seroconverters in the AHRI 
population health surveillance and HIV incidence -based ACDIS cohort were linked to the HIV 
treatment and care program database, using their South African identification number (or if 
missing, full names, sex, and birth date) to the local public sector treatment program database 
(ARTemis). Linkage-to-care is defined in this study as having a first CD4 count test performed 
following HIV infection, as per the Hlabisa Treatment and Care Program’s protocol.  
 Time to linkage-to-care was explored using time- varying covariates. The dynamic nature 
of the AHRI populationACDIS cohort is captured through exposure episodes. Specifically, an 
exposure episode starts on the first day of the year and usually ends on the last day of that 
calendar year. If an individual changes residency or migrates inside or outside of the surveillance 
area, a new exposure episode is created for that time period. Exposure episodes are thus of 
variable lengths and seroconverters can only live in one residencebe a resident of one household 
at a time (but multiple household memberships are allowed). For each of these exposure 
episodes, we were able to assign seroconverters time-invariant and time-varying individual-level 
and household-level characteristics. All individuals who migrated out of the surveillance area, 
even temporarily, were censored on their emigration day. If an individual’s infection date was 
estimated to have occurred while outside of the surveillance area, this person was excluded. 
Hence, the ten10 randomly imputed datasets may have slightly different sample sizes and 
person-time of follow-up. In the event thatIf seroconverters were not found to be linked to 
HIVART care, they were censored on their last day of follow-up, the date they died, or January 
2014 – whichever occurred first. 
 The main outcome of this study is time from HIV infection to linkage-to-care. The only 
time-invariant variables considered are gender, knowledge of HIV status at baseline (i.e., first 
positive test), and the calendar year of infection. Time-varying variables are: age, area of 
residence (urban, peri-urban, rural), socio-economic status (asset-based index categorized into 
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quartiles, among seroconverters, using the first axis of a principal component analysis of 21 
household assets), education level (none or less than one year, some or completed primary, and 
some or completed secondary), whether one’s household co-members are receivingon ART (yes, 
no), and the Euclidian distance to the closest health facility where ART isare provided .(<2 km, 
between 2 and 4 km, and >4 km). Since some of the exposure episodes are retrospectively 
constructed (i.e., they are within two survey dates), we assigned them based on the closest survey 
date (but not more than one year after the beginning of the exposure episode). Household-level 
variables were attributed based on household residence and closest survey date. For missing 
education level values, if an individual was aged 19 years or above and had at least one 
observation with information on education level, we imputed that value using the previously 
reported education level.  
Statistical analyses 
 Time from HIV infection to linkage-to-care was first explored using Kaplan-Meier 
estimates of the survival curve. CD4 counts at linkage, stratified by time to linkage-to-care, were 
also examined. Cox proportional hazards models were then used to estimate the effect size 
measure of the different variables on time to linkage-to-care. Covariates with missing 
observations were retained in the analysis using the missing indicator method [26]. We present 
results for univariate and multivariable models. Because the question about knowledge of HIV 
status was not part of the questionnaire in 2004 and 2005, the multivariable model only included 
observations from individuals who seroconverted from 2006 onwards. The method of Grambsch 
and Therneau [27], based on the scaled Schoenfeld residuals, was used to test that all variables 
met the proportional hazards assumption. Because some covariates failed that test, we stratified 
all the survival analyses using the calendar year of HIV infection to resolve the issue. After 
stratification all covariates met the proportional hazards assumption. All analyses were 
performed individually on the 10 imputed datasets and results were combined using with Rubin’s 
rule [28] using . All analyses were performed using the R statistical software  [29]. and tThe 
‘survival’ package [30] was used to fit the Cox proportional hazards models.  
Ethics 
 All respondents provided informed consent. The Biomedical Research Ethics Committee 
of the University of KwaZulu-Natal granted ethical approval for data collection. 
RESULTS 
 Among individuals that were believed to have seroconverted between August 2004 and 
December 2013, 10 were found to have been linked to care before their last negative test and 
were therefore excluded from our analyses. Since they were potentially outside of the Hlabisa 
Treatment and Care Program’s catchment area, individuals not recorded to be in the surveillance 
area at their estimated time of HIV infection were also excluded. Hence, and depending on the 
randomly imputed seroconversion dates, between 1,713 and 1,779 recent seroconverters 
contributed between 4,582 and 4,818 person-years of follow-up to our inferences. Results from 
the midpoint imputation and the 10 pooled randomly imputed datasets differed principally with 
regards to the uncertainty around the different estimates but not with regard toregarding the 
effect size estimates (see supplemental material Tables S2-S4 and Figures S1-S2). 
 Baseline characteristics of recent seroconverters are presented in Table 1 (midpoint 
imputation). The great majority (77%) of recent seroconverters were women, mean age at HIV 
infection was 27 years old, and over 70% had some or completed secondary education. Mean age 
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at HIV infection was 27 years. Most recent seroconverters did not have members of their 
household who hadhaving initiated ART.  and 63% of seroconverters responded that they were 
aware of their HIV status at the time of their first positive test. The highest numbers of 
seroconversions were observed in 2007 and 2008. The median time between last negative test 
and first positive HIV test was 2.0 years (interquartile range (IQR): 1.1-3.2 years; with a 
maximum of 10 years). 
 Averaging over the imputed datasets, the median follow-up time was 2.2 years (IQR 1.1-
3.9) and only 314% of those who were followed-up for a minimum of six 12 months had a CD4 
count test performed within that time-period (this rises to 14% for 12 months of follow-up and to 
29% two years after HIV infection). Among those whothat had a CD4 count test performed, the 
median time to linkage-to-care was 1.6 years (95% confidence intervals (CI): 1.5 to 1.8). At 
linkage, the median CD4 count was 350 cells/μL (95% CI: 330 to 380) (Table 2). Seroconverters 
that were linked to care in less than one year had a higher median CD4 cell count higher (370 
cells/μL; 95% CI: 320 to 410) than those that linked more than five years after infection (290 
cells/μL; 95%CI: 160 to 430). A total of 40 recent seroconverters died before being linked to 
care after a median follow-up time of 3.0 years (IQR: 1.9-4.7) after infection. The pooled 
Kaplan-Meier estimates of time from HIV infection to linkage-to-care are presented in Figure 1. 
From this, we estimate that it would have taken an average of 4.9 years (95% CI: 4.2 to 5.7) for 
50% of seroconverters to be linked to care (Table 3). After nine years of follow-up, the 
proportion of seroconverters linked to care reached a maximum of 64% (95%CI: 50-79%). Time 
to linkage-to-care differed by gender: it took about 1.7 years (95% CI: 1.5-2.0) for 25% of 
women to link to care versus 3.4 years (95% CI: 2.4-4.4) for men. Time to linkage-to-care also 
decreased with calendar time with 25% of seroconverters linking in 3.7 years (95% CI: 2.4-5.0) 
for those who acquired their infection in 2004 to 1.4 years (95% CI: 0.6-2.2) for those who did 
so in 2010. 
 In univariate analyses, the main determinants of time to linkage-to-care were gender, age, 
education level, and knowledge of HIV status from previous testing (Table 4). Of these 
variables, education level remained only marginally statistically significant in the full 
multivariable model. As compared with females, males had roughly half the hazards of being 
linked to care (adjusted Hazard Ratio [aHR]=0.49; 95%CI 0.37-0.64). Seroconverters in the 40-
49 years of age category had hazards 54% higher (95%CI: 14-% to 108%) of being linked to care 
as compared to seroconverters aged 15-29 years old. Individuals with some or completed 
secondary education had lower hazards of being linked to care than those with a year or less of 
education, although this trend was only marginally significant (aHR=0.63; 95%CI: 0.39-1.00). 
Household co-memberships with individuals who had previously initiated ART increased the 
hazards of being linked to care by 23% (95%CI: -2 to -% to- 55%) but the confidence intervals 
of this estimate crossescrossed the nullis effect was marginally significant. Finally, the hazards 
of being linked to care for individuals that are aware of their HIV status from previous testing 
were 35% (95%CI: 9 to -% to 68%) higher than those whothat were unaware of their status or 
whothat refused to answer the survey question. 
 
DISCUSSION 
 We estimated that it has taken an average of 4.9 years for 50% of seroconverters to be 
linked to care during 2004-2013., period during which these individuals contributed to onward 
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HIV transmission. Among all recent seroconverters that had a CD4 count test performed, the 
median time to linkage-to-care was 1.6 years. CMeaningful comparisons with other empirical 
data settings is difficult because time to linkage-to-care has been defined in the past using HIV 
diagnosis as the starting point. To the best of our knowledge, this study is the first to 
measuredefine time to linkage-to-care using a direct n estimated of the HIV infection date as a 
starting point. The longitudinal HIV status data for this study was generated in one of Africa’s 
largest population-based HIV incidence cohorts. Our empirical estimate of among a population-
based cohort of repeated testers. This first directly measured empirical estimate of time from 
HIV infection to linkage is highly policy-relevant because it is a minimum bound on the length 
of time during which HIV-positive individuals can transmit HIV before the transmission risk is 
potentially eliminated through HIV treatment [31]. Our results indicate that substantial linkage 
improvements will be needed to maximize population-level benefits of both HIV treatment and 
HIV treatment-as-prevention. 
 With close to a quarter of patients dying within their first year on ART [31], not only is 
earlier initiation required, but also earlier diagnosis. We estimated that the median CD4 counts at 
linkage-to-care wasere of 370 cells/μL for individuals linking within one year of HIV infection 
and 290 cells/μL for those linking five years or more after HIV of infection, as opposed to 290 
cells/μL for individuals linking five years or more after HIV infection. A number ofSeveral 
reasons could explain that the median CD4 count for individuals linking to care within one year 
was below 500 cells/μL. First, the observed time lag between the last negative and first positive 
HIV test had a median of 2 years. Non-differential misclassification of the date of HIV infection 
could have biased our results toward the overall median CD4 count of individuals linking to care. 
Second, rates of decline in CD4 counts follow an unobserved distribution that we are able tocan 
estimate only among those individuals who linked to care. If linkage is a function of health 
status, which has been shown in other studies [15, 32], those with rapid disease progression, and 
lower CD4 cell counts, will link to care faster. The resulting median CD4 cell count since time 
from HIV infection is thus likely lower among our sample of individuals that linked to care than 
the median CD4 cell count since time from HIV infection among all HIV-positive people.  
This alternate definition provides more relevant data contributing to our understanding of 
HIV epidemiology and its transmission dynamics. Another limitation of the extant literature that 
our study is addressing is that HIV testing and diagnosis can, at least partly, be a function of 
health status and treatment-seeking behavior, leading to endogeneity biases when the date of 
diagnosis is used in survival analysis of the determinants of linkage-to-care. Our approach, 
which is based on the date of HIV infection rather than the diagnosis date, corrects for this 
potentially important bias. Moreover, time from HIV infection to linkage-to-care is important for 
policy making. The shorter this time, the higher are the chances of successful HIV treatment. 
Additionally, this time is an important determinant of the success of HIV treatment-as-
prevention strategies, because it is the time during which an HIV-positive individual can 
contributes to transmissiontransmit the HIV virus. Our median estimate of a 5 years delay from 
HIV infection to linkage-to-care, results indicates that substantial linkage improvements will be 
needed to maximize population-level benefits of HIV treatment-as-prevention. 
 With close to a quarter of patients dying within their first year on ART treatment [31], 
not only is earlier initiation required, but also earlier diagnosis. We estimated that the median 
CD4 count at linkage-to-care was of 370 cells/μL for individuals linking within one year of 
infection, as opposed to 290 cells/μL for individuals linking five years or more after HIV 
Formatted: Indent: First line:  0.5"
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infection. A number of reasons could explain that the median CD4 count for individuals linking 
to care within one year was below 500 cells/μL. First, the observed time lag between the last 
negative and first positive HIV test had a median of 2 years. Non-differential misclassification of 
the date of HIV infection could have biased our results toward the overall median CD4 cell count 
of individuals linking to care. Second, rates of decline in CD4 counts follow an unobserved 
distribution that we are able to estimate only among those individuals who linked to care. If 
linkage is a function of health status, which has been shown in other studies [15, 32], those with 
rapid disease progression, and lower CD4 cell counts, will link to care faster. The resulting 
median CD4 cell count since time from HIV infection is thus likely lower among our sample of 
individuals that linked to care than the median CD4 cell count since time from HIV infection 
among all HIV-positive people.  
 In this mostly poor and rural population, rates of linkage-to-care were twice as high for 
females as those of males, substantiating previous research [5, 6, 33]. The same was true for age, 
with seroconverters in the 40-49 years old range having the highest rates of linkage-to-care. 
Individuals with more education were found to be less likely to link to HIV care, although this 
was only marginally significant. Having other household members who previously initiated ART 
also had a marginally significant effect ontended to reduce time to linkage-to-care. This finding 
provides some limited evidence that family and social exposure HIV treatment to the Hlabisa 
Treatment and Care Program can facilitate linkage and ould bolster ART uptake. 
 Not surprisingly, one’s knowledge of his/her HIV status from previous testing was a 
strong predictor of linkage to HIV care. Diagnosing HIV is the first, and necessary step, on the 
HIV treatment cascade. We estimated that 63% of individuals were aware of their HIV status at 
their first positive HIV test during the annual sero-surveys and this was a predictor of linkage-to-
care. Yet, linkage-to-care was low and delayed in this cohort of seroconverters. This finding 
could be partly due to the eligibility criteria for ART from 2004 to 2010. During those years, 
only individuals with CD4 count less than 200 cells/μL were eligible for ART initiation. 
Compounding this effect are the previously described low pre-ART retention rates [16] and high 
disengagement from care in this cohort [11]. These findings are corroborated by those from the 
first phase of the ANRS 12249 treatment-as-prevention trial, conducted in the same area as this 
study, which showed that the delays in linkage-to-care could compromise the population-level 
effectiveness of treatment-as-prevention [8, 9]. Preliminary results from the trial suggest that 
treatment-as-prevention did not substantially reduce HIV incidence because ART coverage in 
both arms of the trial were similar [8, 9]. That is, the intervention failed to link-to-care a 
substantial proportion of people in early HIV infection stages. Our estimates of time to linkage-
to-care are nevertheless different than those from this trial because the latter did not define time 
to linkage based on date of HIV infection but date of diagnosis (the trial was not powered to 
examined time from HIV infection to linkage-to-care). Here, we provide direct evidence of 
important delays in time from HIV infection to linkage-to-care. Although these delays have 
tended to decrease with time, we estimated that the proportion of seroconverters linked to care 
would still be substantially lower than the UNAIDS target with a maximum proportion of 64% 
of seroconverters linked to care after the maximum observed follow-up of nine years. 
 Great challenges will need to be overcome to maximize the public health benefits of ART 
in such settings such as the community in which this study took placeand to reach UNAIDS’s 
90-90-90 objective. A number ofSeveral potential solutions have been proposed from point-of-
care CD4 testing with home-based counseling and testing to health systems interventions and 
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financial incentives [34, 35]. Yet, the quality of evidence for these proposed interventions is low 
and interventions often only target a single point in the HIV care continuum [34, 35]. It is also 
unlikely that a single intervention could efficiently address all barriers to timely linkage-to-care 
[36]. More research is needed into multi-pronged approaches that would mitigate the individual, 
community, and structural barriers that delay linkage-to-care. 
 This study has some limitations. First, the exact date of HIV infection remains unknown 
and was estimated based on individuals who repeatedly participated in the annual population 
HIV surveillance surveys. Yet, random imputation of infection dates, resulting in non-differential 
measurement errors in time-to-event, generally introduces only small bias in the hazard ratio 
estimates [37, 38]. Further, we randomly imputed 10 datasets and the summary estimates we 
present included this imputation uncertainty. Second, we cannot totally rule out that some 
individuals found to have seroconverted sought care outside of the Hlabisa Treatment and Care 
Program. Nevertheless, it is unlikely that the proportion of HIV positive individuals accessing 
ART outside of this public- sector program is higher than a few percent [24]. LMoreover, low 
rates of health insurance makes private health care utilization, in particular for chronic diseases 
such as HIV, of ART  rare in this community [24]. 
 An important strength of this research is the use of population-based data, from one of 
Africa’s largest population-based HIV incidence cohorts,  to estimates the time from HIV 
infection toof HIV linkage-to-care. Such estimates are likely potentially less biasedmore 
representative of the the full population of HIV-positive individualpopulations in a community 
than those derived from facility-based data. Other strengths include the definition of time to 
linkage-to-care based on date of HIV infection. To the best of our knowledge, this is the first 
study to use this definition, instead of the date of HIV diagnosis, which that is likely to could 
potentially lead to substantial underestimates of time to linkage.biased estimates. Using a cohort 
of repeated testers to estimate infection date is also more accurate than other approaches, such as 
back-calculation of seroconversion date based on CD4 cell counts at ART initiation or 
estimations based on tests for recent infections, which could introduce additional errors [39, 40]. 
Finally, we addressed a limitation of the extant literature on the determinants of linkage-to-care. 
Because HIV testing and diagnosis can, at least partly, be a function of health status and 
treatment-seeking behavior, using the date of diagnosis in survival analysis could lead to 
endogeneity biases. Our approach, based on the date of HIV infection rather than the diagnosis 
date, corrects for this potential bias.  
 In conclusion, large reductions in the time from HIV infection to linkage-to-care are 
required to realize the full potential of HIV treatment and HIV treatment-as-prevention in 
improving population health. iIncreasing HIV testing uptake and frequency, as well as targeted 
interventions to improve linkage-to-care, in particular for men and young individuals, couldare 
likely good candidate interventions for shortening the time from infection to the first HIV clinic 
visit  be considered to facilitate earlier linkage to HIV care after infection [41]. Without timely 
linkage-to-care, the population-level impact of treatment-as-prevention is unlikely to 
significantly reduce HIV incidence in this population.  
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Table 1: Baseline characteristics of recent seroconverters (using midpoint imputation; N=1,733) 
residing in the demographic surveillance area, South Africa (2004-2013). 
Variables Mean (SD) or Total (%) 
Gender  
   Female 1,333 (76.9%) 
   Male 400 (23.1%) 
Age (years) 26.8 (10.5) 
Education level  
   None or less than one year 103 (5.9%) 
   Some or completed primary 269 (15.5%) 
   Some or completed secondary 1,289 (74.4%) 
   Missing 72 (4.2%) 
Socio-economic status  
   Poorest  374 (21.6%) 
   Poor 435 (25.1%) 
   Rich 488 (28.2%) 
   Richest 435 (25.1%) 
   Missing 1 (0.1%) 
Food security  
   Never (or some months) missed meals 1,675 (96.7%) 
   Missing meals almost every month (financial reasons) 47 (2.7%) 
   Missing 11 (0.6%) 
Uptake of ART by household members  
   No household members on ART 1,463 (84.4%) 
   At least one household member on ART 270 (15.6%) 
Knowledge of HIV Status*  
   Aware 917 (63.3%) 
   Unaware / Refused  537 (36.7%) 
Area of residence  
   Urban 52 (3.1%) 
   Peri-urban 619 (35.7%) 
   Rural 1,061 (61.2%) 
Distance to closest health facility (km) 6.0 (9.1) 
Calendar year of HIV infection  
   2004 81 (4.7%) 
   2005 198 (11.4%) 
   2006 240 (13.8%) 
   2007 259 (14.9%) 
   2008 262 (15.1%) 
   2009 207 (11.9%) 
   2010 180 (10.4%) 
   2011 153 (8.8%) 
   2012 129 (7.4%) 
   2013 24 (1.4%) 
*The question about knowledge of HIV status from previous testing was not asked in 2004 
and 2005 (279 seroconverters were excluded). 
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Table 2: Median CD4 cell count (cells/μL) at linkage, stratified by linkage time since HIV 
infection, with 95% bootstrapped confidence intervals. 
Time from HIV infection to 
linkage-to-care 
Median CD4 cells/μL 
(95% CI*) 
Less than one year 370 (320, 410) 
Between one and two years 380 (340, 420) 
Between two and three years 360 (290, 430) 
Between three and four years 310 (230, 390) 
Between four and five years 320 (220, 410) 
More than five years 290 (160, 430) 
Overall 350 (330, 380) 
*95%CI=95% confidence intervals. These are based on 9,999 
bootstrap replicates. 
 
 
Table 3: Time from HIV infection (years) to linkage to care stratified by gender and calendar 
year of HIV infection. 
Characteristics 
Time from HIV 
infection for 25% of 
seroconverters to link to 
care (95% CI*) 
Time from HIV 
infection for 50% of 
seroconverters to link to 
care (95% CI*) 
Gender   
   Females 1.7 (1.5-2.0) 4.2 (3.7-4.6) 
   Males 3.4 (2.4-4.4) NA† 
Calendar year of HIV infection   
   2004 3.7 (2.4-5.0) 6.1 (3.7-8.5) 
   2005 3.1 (2.4-3.8) 5.6 (4.2-7.1) 
   2006 2.3 (1.7-2.9) 4.6 (3.3-6.0) 
   2007 1.6 (1.0-2.3) 4.0 (2.7-5.4) 
   2008 1.5 (1.0-2.0) NA† 
   2009 1.6 (1.0-2.2) NA† 
   2010 1.4 (0.6-2.2) NA† 
Overall 2.0 (1.8-2.2) 4.9 (4.2-5.7) 
 
*95%CI=95% confidence intervals. These are based on 9,999 bootstrap replicates. 
†NA=not available (the follow-up time was not long enough to observe 50% of seroconverters 
linking to care). 
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Figure 1. Pooled Kaplan-Meier estimates of time from HIV infection to linkage-to-care in rural 
Kwa-Zulu Natal South Africa (2004-2013) for A) all seroconverters and B) stratified by gender. 
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Table 4: Univariate and multivariable effect size estimates from Cox proportional hazard models 
of determinants of time from HIV infection to linkage-to-care in rural Kwa-Zulu Natal, South 
Africa. (Pooled results from the 10 imputed datasets.) 
Variables Univariate Multivariable* HR (95% CI) aHR (95% CI) 
GENDER   
   Male 0.49 (0.39-0.61) 0.49 (0.37-0.64) 
AGE   
   15-29 years old 1.00 1.00 
   30-39 years old 1.22 (0.96-1.55) 1.16 (0.86-1.57) 
   40-49 years old 1.92 (1.53-2.40) 1.54 (1.14-2.08) 
   50+ years old 1.15 (0.80-1.64) 0.87 (0.53-1.44) 
EDUCATION LEVEL   
   None or less than one year 1.00 1.00 
   Some or completed primary 0.87 (0.61-1.25) 0.75 (0.46-1.22) 
   Some or completed secondary 0.68 (0.50-0.93) 0.63 (0.39-1.00) 
FOOD SECURITY   
   Missing meals almost every month (financial reasons) 1.56 (0.88-2.79) 1.37 (0.67-2.80) 
SOCIO-ECONOMIC STATUS    
   Poorest 1.00 1.00 
   Poor 1.15 (0.90-1.46) 1.21 (0.91-1.61) 
   Rich 1.14 (0.90-1.44) 1.19 (0.75-1.90) 
   Richest 1.00 (0.78-1.29) 1.05 (0.62-1.79) 
OTHER HOUSEHOLD MEMBERS USING ART   
   At least one (versus ‘None’) 1.16 (0.96-1.41) 1.23 (0.98-1.55) 
KNOWLEDGE OF HIV STATUS*   
   Yes (versus ‘No / Refused’) 1.52 (1.24-1.87) 1.35 (1.09-1.68) 
AREA OF RESIDENCE   
   Urban 1.00 1.00 
   Peri-Urban 0.65 (0.42-1.02) 0.73 (0.43-1.24) 
   Rural 0.77 (0.49-1.21) 0.76 (0.45-1.30) 
DISTANCE TO HEALTH FACILITY   
   <2 km 1.00 1.00 
   2 to 4 km 1.04 (0.86-1.25) 1.00 (0.79-1.26) 
   >4 km 1.16 (0.93-1.45) 1.10 (0.84-1.44) 
CALENDAR YEAR OF HIV INFECTION Included as strata Included as strata 
 
HR (95% CI)=Hazard Ratio (95% Confidence Interval); aHR=adjusted Hazard Ratio. 
Results are presented after pooling the analyses of the 10 imputed datasets. All models were stratified using the 
calendar year of HIV infection to ensure that the proportional hazards assumption was met. The model’s outcome 
variable was the time from HIV infection to linkage-to-care. We used ; the latter was defined using the date of the first 
CD4 count test was performed in the local HIV treatment and care program to identify the time from infection to 
linkage. 
*The question about knowledge of HIV status from previous testing was not asked in 2004 and 2005, hence, 
observations from these years were not included in the multivariable model. 
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must be at or before the enrollment of participants. The editors of AIDS also do not advocate 
one particular registry but require that the registry utilized meet the criteria set out in the 
statement of policy of the ICMJE (www.ijcme.org). 
 
Please state that your article includes a clinical trial and that the conditions of submission 
above have been met. 
► No, this is observational data. 
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